Co-Diagnostics (CODX) Q2 2026 Earnings Call: FDA Filing Advances as Cash Falls

Co-Diagnostics advanced its FDA dual 510(k) and CLIA waiver application for its influenza and RSV assay while reporting narrowed losses and lower operating expenses in Q2 2026. The company faces cash challenges with $3.6 million remaining and plans capital raises, also targeting tuberculosis submissions to India and WHO later in 2026.

This Wire brief sits within Fusion42's coverage of Diagnostics.